Janux Therapeutics Inc (JANX)
55.80
+1.41
(+2.59%)
USD |
NASDAQ |
Nov 04, 16:00
56.00
+0.20
(+0.36%)
After-Hours: 20:00
Janux Therapeutics Enterprise Value: 2.264B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 2.264B |
| November 01, 2024 | 2.191B |
| October 31, 2024 | 2.170B |
| October 30, 2024 | 2.272B |
| October 29, 2024 | 2.182B |
| October 28, 2024 | 2.189B |
| October 25, 2024 | 2.140B |
| October 24, 2024 | 2.135B |
| October 23, 2024 | 2.053B |
| October 22, 2024 | 2.108B |
| October 21, 2024 | 1.987B |
| October 18, 2024 | 1.963B |
| October 17, 2024 | 1.952B |
| October 16, 2024 | 1.931B |
| October 15, 2024 | 2.105B |
| October 14, 2024 | 1.928B |
| October 11, 2024 | 1.938B |
| October 10, 2024 | 1.817B |
| October 09, 2024 | 1.753B |
| October 08, 2024 | 1.697B |
| October 07, 2024 | 1.657B |
| October 04, 2024 | 1.702B |
| October 03, 2024 | 1.658B |
| October 02, 2024 | 1.620B |
| October 01, 2024 | 1.675B |
| Date | Value |
|---|---|
| September 30, 2024 | 1.724B |
| September 27, 2024 | 1.766B |
| September 26, 2024 | 1.786B |
| September 25, 2024 | 1.852B |
| September 24, 2024 | 1.888B |
| September 23, 2024 | 1.975B |
| September 20, 2024 | 1.972B |
| September 19, 2024 | 1.961B |
| September 18, 2024 | 1.874B |
| September 17, 2024 | 1.934B |
| September 16, 2024 | 1.956B |
| September 13, 2024 | 1.962B |
| September 12, 2024 | 1.781B |
| September 11, 2024 | 1.634B |
| September 10, 2024 | 1.728B |
| September 09, 2024 | 1.537B |
| September 06, 2024 | 1.506B |
| September 05, 2024 | 1.634B |
| September 04, 2024 | 1.673B |
| September 03, 2024 | 1.702B |
| August 30, 2024 | 1.804B |
| August 29, 2024 | 1.682B |
| August 28, 2024 | 1.660B |
| August 27, 2024 | 1.710B |
| August 26, 2024 | 1.774B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-79.73M
Minimum
Nov 09 2023
2.707B
Maximum
May 03 2024
601.62M
Average
303.28M
Median
Jul 25 2023
Enterprise Value Benchmarks
| Dynavax Technologies Corp | 1.033B |
| Krystal Biotech Inc | 4.349B |
| Arcus Biosciences Inc | 453.61M |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Palatin Technologies Inc | 13.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.959M |
| Revenue (Quarterly) | 8.897M |
| Total Expenses (Quarterly) | 22.72M |
| EPS Diluted (Quarterly) | -0.11 |
| Profit Margin (Quarterly) | -66.98% |
| Earnings Yield | -1.61% |
| Normalized Earnings Yield | -1.613 |